Examkin

Soru

Zorluk: KolayClinical Preventive Services and Screening

A 52-year-old woman presents to the clinic for a routine well-woman examination. She has no significant past medical history and takes no daily medications. She went through menopause 2 years ago and has experienced no vaginal bleeding or spotting since that time. She had a normal screening colonoscopy at age 50 and a normal Papanicolaou (Pap) test with human papillomavirus (HPV) co-testing at age 50. She has not had a mammogram in the past 3 years. Her vital signs and physical examination are unremarkable.

Which of the following is the most appropriate next step in preventive care for this patient?

  1. Screening mammographyCevap
  2. B
    Endometrial biopsy
  3. C
    Cervical cytology with human papillomavirus co-testing
  4. D
    Live-attenuated influenza vaccine
  5. E
    Dual-energy x-ray absorptiometry

Cevap

Screening mammography
The most appropriate next step in preventive care for this patient is screening mammography. According to current United States Preventive Services Task Force (USPSTF) guidelines, biennial (every 2 years) screening mammography is recommended for women aged 40 to 74 years. Because this patient is 52 years old and her last mammogram was 3 years ago, she is currently overdue for this routine screening.

Adım Adım Çözüm

1
Evaluate the patient's demographic profile and prior screening timeline.
The patient is a 52-year-old asymptomatic woman who had her last mammogram 3 years ago.
Preventive care recommendations are heavily dependent on age, sex, and the time elapsed since the last screening.
2
Compare her history against current USPSTF guidelines for breast cancer screening.
The USPSTF recommends biennial (every 2 years) screening mammography for women aged 40 to 74 years.
Identifying the guideline establishes whether the patient is due or overdue for the intervention.
3
Review other options to ensure no other preventive interventions take higher priority or are incorrectly timed.
Her colonoscopy (due every 10 years) and Pap/HPV co-testing (due every 5 years) are up to date. DEXA is premature, and LAIV is inappropriate for her age.
Proper screening requires not only ordering the right tests but also avoiding unnecessary, premature, or contraindicated procedures.

Anahtar Kavram

The United States Preventive Services Task Force (USPSTF) recommends biennial screening mammography for women aged 40 to 74 years.
Bu soruyu puanla

Konular

Clinical Preventive Services and Screening

Bu konudan daha fazla soru